Physician profile
James E Fairlamb
NPI 1326029745
$341,811.84
in general payments reported to CMS, 2019-2025
31 companies · $10K in 2025
The $10K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85K · 2020: $68K · 2021: $57K · 2022: $53K · 2023: $43K · 2024: $26K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Travel and Lodging: $12K · Food and Beverage: $5,505 · Education: $21.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,736.50 |
| Travel and Lodging | $12,003.46 |
| Food and Beverage | $5,505.11 |
| Education | $21.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $132,011.95 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71,320.66 | 2019-2025 | Jardiance |
| Pfizer INC. | $49,861.06 | 2019-2023 | |
| Amarin Pharma, INC. | $39,794.67 | 2019-2021 | |
| Lilly USA, LLC | $20,429.03 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $10,864.53 | 2020-2025 | Wainua |
| Sanofi-Aventis U.S. LLC | $5,471.31 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $3,445.84 | 2019-2025 | |
| Boston Scientific Corporation | $2,999.42 | 2019-2024 | Watchman Flx, Watchman Access System, Bodyguardian |
| Biotronik INC. | $1,975.12 | 2023-2025 | Biomonitor, Amvia Edge, Selectra |
| Regeneron Healthcare Solutions, INC. | $991.97 | 2019-2025 | Evkeeza |
| E.R. Squibb & Sons, L.L.C. | $340.04 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $318.50 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $255.36 | 2021-2024 | |
| Cvrx, INC. | $229.31 | 2024 | Barostim Neo System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $221.25 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $205.14 | 2019-2020 | |
| Medtronic, INC. | $193.68 | 2023-2024 | Onyx Frontier, Micra |
| Alnylam Pharmaceuticals INC. | $189.04 | 2024-2025 | Amvuttra |
| Impulse Dynamics (USA) INC. | $170.18 | 2023 | Optimizer |
| Scpharmaceuticals INC. | $107.98 | 2024 | |
| Edwards Lifesciences Corporation | $90.21 | 2023-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Actelion Pharmaceuticals US, INC. | $77.87 | 2020 | |
| Abbott Laboratories | $73.00 | 2019-2020 | |
| Genzyme Corporation | $58.30 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $50.76 | 2024-2025 | Verquvo |
| Abiomed | $21.57 | 2025 | |
| Daiichi Sankyo INC. | $17.54 | 2023 | Injectafer |
| Esperion Therapeutics, INC. | $13.79 | 2025 | Nexletol |
| Shockwave Medical, INC | $12.76 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fairlamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.